Firmonertinib
Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.
| Trivial name | Alflutinib, Furmonertinib, AST2818 |
| Catalog Number | E5881 |
| Molecular Formula | C15H24N4O6S2.H2O |
| CAS# | 1869057-83-9 |
| Inchi | InChI=1S/C15H24N4O6S2.H2O/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25;/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25);1H2/t6-,7-,8+,9+,10-,11-;/m1./s1 |
| Inchi Key | NTUBEBXBDGKBTJ-WGLOMNHJSA-N |
| SMILES | CC1C2C(C(=O)N2C(=C1SC3CC(NC3)CNS(=O)(=O)N)C(=O)O)C(C)O.O |
| Size | 5mg |
| Supplier Page | http://www.selleckchem.com/products/firmonertinib.html |
| Additional Information | https://file.selleck.cn/downloads/struct/E5881-Firmonertinib-chemical-structure.png |